Related Experiment Videos
[Heart, diabetes and glitazones].
1Institut de Cardiologie, CHU Pitié-Salpêtrière, F-75651 Paris Cedex 13. claude.lefeuvre@psl.ap-hop-paris.fr
Annales D'Endocrinologie
|May 28, 2004
Summary
Rosiglitazone offers metabolic benefits for type 2 diabetes but carries risks like fluid retention and heart failure. Further studies are needed to assess its long-term cardiovascular impact in high-risk patients.
Area of Science:
- Endocrinology
- Pharmacology
- Cardiology
Background:
- Rosiglitazone is known for beneficial metabolic effects in type 2 diabetes.
- Established adverse events are generally minor or mild.
- Fluid retention and heart failure risk require further investigation.
Purpose of the Study:
- To review the metabolic effects and adverse events of rosiglitazone.
- To detail fluid retention and heart failure risks, including risk factors, clinical characteristics, and pathophysiology.
- To describe preventive measures and ongoing clinical programs assessing cardiovascular outcomes.
Main Methods:
- Review of existing literature on rosiglitazone's metabolic effects and adverse events.
- Detailed analysis of fluid retention and heart failure risk factors and mechanisms.
- Description of planned prospective clinical trials.
Main Results:
- Rosiglitazone has established metabolic benefits.
- Fluid retention and potential heart failure risk are key adverse events.
- Experimental data support further investigation into cardiovascular outcomes.
Conclusions:
- Rosiglitazone's metabolic advantages are well-documented.
- Careful monitoring for fluid retention and heart failure is essential.
- Large-scale studies are crucial to evaluate rosiglitazone's cardiovascular safety and efficacy in high-risk type 2 diabetic patients.